Almac's Ovarian Cancer Patient Stratification Test Could Be Used to Select Treatment for Other Diseases | GenomeWeb

NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.

The company is currently validating the test, which is run on the Affymetrix platform, with the intention of making it available for clinical use next year. Almac also believes the assay could be used to stratify patients suffering from other cancers who have undergone chemotherapy, according to Richard Kennedy, the firm's medical director.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."